Cardiovascular system future

Due to the large number of references which appeared to be worth mentioning, it became necessary to divide this review into two parts. The present part deals mainly with pyridazines as chemotherapeutics, antithrombotics, antise-cretory and anti-ulcer agents, analgesic and anti-inflammatory agents as well as with various central nervous system stimulants and depressants. Part 2 of this review, which is planned for a future volume of this Series, will be devoted mainly to compounds which act on the cardiovascular system and to a discussion of miscellaneous additional pharmacological activities of pyridazine derivatives. 

General. The purpose of the medical procedures outlined in the standard is to establish a baseline for future health monitoring. Persons unusually susceptible to the effects of anoxia or those with anemia would be expected to be at increased risk. In addition to emphasis on the CNS, respiratory and gastro-intestinal systems, the cardiovascular system, liver, and kidney function should also be stressed. 

NO donors have been used for more than a century in the treatment of cardiovascular diseases. Clearly, the NO/cGMP system plays a major role in platelet inhibition in vivo and in vitro, however, the complex regulation of cGM P levels, as well as the crosstalk to the cAMP system, makes it a signaling network that is not yet fully understood. The contribution of cGMP-independent mechanisms in NO signaling in platelets is far from clear. Careful use of the crucial genetically altered mouse models, the variety of NO donors with clear differences in biochemistry and functional platelet effects as well as the many so-called specific activatory or inhibitory research tools will certainly help to elucidate the still unknown areas of NO signaling in platelets in the near future. 

To date, there is no generally accepted theory that accounts for the development of AD pathology. The multifactorial basis of the disease makes such a theory unlikely to be possible in the foreseeable future. In addition to the NFTs and amyloid-hypothesis of the disease, oxidative stress, systemic levels of redox active metal ions, cardiovascular disease, the apoEe4 allele and type 2 diabetes are all clear risk factors for development of AD. However, recent research supports the notion that the Ap buildup may be a key event in AD and that other manifestations of the disease, like NFT formation, result from an imbalance between AP production and AP clearance (17). 

Markers of systemic inflammation (e.g., C-reactive protein [CRP] and interleukin-6 [IL-6]) have been proposed to be nontradi-tional risk factors for cardiovascular disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of atherosclerotic plaque rupture, which raises the possibility of the use of MMP-9 levels as a marker for future MI or UA. In vitro and animal studies suggest that thiazolidinediones can reduce the expression of these markers. Rosiglitazone reduces serum levels of MMP-9 and the proinflammatory marker CRP in patients with type 2 diabetes, which indicates potentially beneficial effects on overall cardiovascular risk. The management of UA and NSTEMI is covered in detail in Chap. 16. 

---